Published in J Hepatol on January 01, 2005
Clinical Food Addiction Is Not Associated with Development of Metabolic Complications in Liver Transplant Recipients. J Clin Transl Hepatol (2017) 0.75
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol (2004) 3.27
Donor and recipient outcomes in right lobe adult living donor liver transplantation. Liver Transpl (2002) 2.98
Hepatic ischemia/reperfusion injury--a fresh look. Exp Mol Pathol (2003) 2.81
Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol (2010) 2.63
Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology (2006) 2.62
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
ASC/caspase-1/IL-1β signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury. Hepatology (2013) 2.45
Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion. Liver Transpl (2010) 2.30
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Incisional hernia after liver transplantation. J Am Coll Surg (2006) 2.23
Surgical privileging and credentialing: a report of a discussion and study group of the American Surgical Association. J Am Coll Surg (2009) 2.18
Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. J Am Coll Surg (2009) 2.16
Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm (2008) 2.16
Ammonia levels and the severity of hepatic encephalopathy. Am J Med (2003) 2.14
Liver transplantation in highest acuity recipients: identifying factors to avoid futility. Ann Surg (2014) 2.13
Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. Transplantation (2015) 2.13
Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg (2007) 2.12
Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology (2005) 2.04
Surgery for hepatocellular carcinoma: does it improve survival? Ann Surg Oncol (2004) 2.01
Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol (2009) 1.97
Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology (2004) 1.80
MELD fails to measure quality of life in liver transplant candidates. Liver Transpl (2005) 1.79
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg (2004) 1.79
Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg (2005) 1.73
Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl (2003) 1.71
Outcome of liver transplantation in septuagenarians: a single-center experience. Arch Surg (2007) 1.69
Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology (2005) 1.66
Endoscopic treatment of postorthotopic liver transplantation anastomotic biliary strictures with maximal stent therapy (with video). Gastrointest Endosc (2010) 1.65
Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg (2008) 1.65
Assessment of hepatic steatosis by transplant surgeon and expert pathologist: a prospective, double-blind evaluation of 201 donor livers. Liver Transpl (2013) 1.62
Ex vivo exposure to carbon monoxide prevents hepatic ischemia/reperfusion injury through p38 MAP kinase pathway. Hepatology (2002) 1.62
Chronic viral hepatitis and hepatocellular carcinoma. World J Surg (2007) 1.62
The protective function of neutrophil elastase inhibitor in liver ischemia/reperfusion injury. Transplantation (2010) 1.62
Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation by the cAMP-PKA pathway. Hepatology (2013) 1.60
Type I, but not type II, interferon is critical in liver injury induced after ischemia and reperfusion. Hepatology (2008) 1.59
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Operative parameters that predict the outcomes of hepatic transplantation. J Am Coll Surg (2003) 1.58
Giant cavernous liver hemangiomas: effect of operative approach on outcome. Arch Surg (2004) 1.58
Predictors of hyperkalemia in the prereperfusion, early postreperfusion, and late postreperfusion periods during adult liver transplantation. Anesth Analg (2007) 1.57
Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology (2010) 1.56
Metalloproteinase-9 deficiency protects against hepatic ischemia/reperfusion injury. Hepatology (2008) 1.55
Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg (2012) 1.55
A caspase inhibitor, IDN-6556, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemia. Liver Transpl (2007) 1.53
Toll-like receptor and heme oxygenase-1 signaling in hepatic ischemia/reperfusion injury. Am J Transplant (2005) 1.51
Treating hepatitis C in the prison population is cost-saving. Hepatology (2008) 1.50
Liver transplantation using organ donation after cardiac death: a clinical predictive index for graft failure-free survival. Arch Surg (2011) 1.50
Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. J Immunol (2002) 1.50
MELD score predicts 1-year patient survival post-orthotopic liver transplantation. Liver Transpl (2003) 1.49
Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl (2004) 1.47
CXCL10 regulates liver innate immune response against ischemia and reperfusion injury. Hepatology (2008) 1.46
Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr (2007) 1.46
CD154-CD40 T-cell costimulation pathway is required in the mechanism of hepatic ischemia/reperfusion injury, and its blockade facilitates and depends on heme oxygenase-1 mediated cytoprotection. Transplantation (2002) 1.45
Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant (2002) 1.44
Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J Urol (2004) 1.43
Molecular mediators of liver ischemia and reperfusion injury: a brief review. Mol Med (2008) 1.43
Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol (2009) 1.42
Ischaemia-reperfusion injury in liver transplantation--from bench to bedside. Nat Rev Gastroenterol Hepatol (2012) 1.39
Kidney transplantation threshold in patients with hepatitis C: a decision analysis model. Transplantation (2015) 1.38
Severe hepatotoxicity due to Hydroxycut: a case report. Dig Dis Sci (2008) 1.38
RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy. J Gene Med (2010) 1.38
Biliverdin therapy protects rat livers from ischemia and reperfusion injury. Hepatology (2004) 1.37
Prevalence of metastases in hepatocellular carcinoma: risk factors and impact on survival. Am Surg (2003) 1.37
Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol (2008) 1.37
Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg (2006) 1.36
Treatment of hepatitis C. Am J Med (2005) 1.35
Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology (2007) 1.31
Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury in mice: HO-1 dependence of Stat4 disruption-mediated cytoprotection. Hepatology (2003) 1.29
Long-term patient outcome and quality of life after liver transplantation: analysis of 20-year survivors. Ann Surg (2010) 1.28
Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol (2003) 1.27
Heme oxygenase-1 system in organ transplantation. Transplantation (2002) 1.26
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer (2011) 1.26
Severe psychiatric problems in right hepatic lobe donors for living donor liver transplantation. Transplantation (2007) 1.26
Heme oxygenase-1 overexpression protects rat hearts from cold ischemia/reperfusion injury via an antiapoptotic pathway. Transplantation (2002) 1.25
Heme oxygenase-1 gene transfer inhibits inducible nitric oxide synthase expression and protects genetically fat Zucker rat livers from ischemia-reperfusion injury. Transplantation (2002) 1.24
Fulminant hepatic failure from primary hepatic lymphoma: successful treatment with orthotopic liver transplantation and chemotherapy. Transplantation (2005) 1.23
Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg (2002) 1.22
CD4 T cells promote tissue inflammation via CD40 signaling without de novo activation in a murine model of liver ischemia/reperfusion injury. Hepatology (2009) 1.22
Absence of toll-like receptor 4 (TLR4) signaling in the donor organ reduces ischemia and reperfusion injury in a murine liver transplantation model. Liver Transpl (2007) 1.22
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Hepatocellular carcinoma: microwave ablation with multiple straight and loop antenna clusters--pilot comparison with pathologic findings. Radiology (2006) 1.20
Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg (2006) 1.20
Postresection hepatic failure: successful treatment with liver transplantation. Liver Transpl (2007) 1.20
HO-1-STAT3 axis in mouse liver ischemia/reperfusion injury: regulation of TLR4 innate responses through PI3K/PTEN signaling. J Hepatol (2011) 1.19
Evidence for the pivotal role of endogenous toll-like receptor 4 ligands in liver ischemia and reperfusion injury. Transplantation (2008) 1.17
Viral hepatitis in incarcerated adults: a medical and public health concern. Am J Gastroenterol (2009) 1.17
T-cell immunoglobulin mucin-3 determines severity of liver ischemia/reperfusion injury in mice in a TLR4-dependent manner. Gastroenterology (2010) 1.16
Longterm outcomes for whole and segmental liver grafts in adult and pediatric liver transplant recipients: a 10-year comparative analysis of 2,988 cases. J Am Coll Surg (2009) 1.15
Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg (2003) 1.15
Intraoperative triple antenna hepatic microwave ablation. AJR Am J Roentgenol (2006) 1.15